ALIGOS THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

ALIGOS THERAPEUTICS INC share price today is $6.81, up -7.22%. The stock opened at $7.05 against the previous close of $7.34, with an intraday high of $7.05 and low of $6.88.

ALIGOS THERAPEUTICS INC Share Price Chart

ALIGOS THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

ALIGOS THERAPEUTICS INC Share Price Performance

$6.81 -0.0722(-7.22%) ALGS at 23 Mar 2026 11:57 AM Biotechnology
Lowest Today 6.88
Highest Today 7.05
Today’s Open 7.05
Prev. Close 7.34
52 Week High 13.69
52 Week Low 3.76
Day’s Range: Low 6.88 High 7.05
52-Week Range: Low 3.76 High 13.69
1 day return -
1 Week return -9.93
1 month return +0.14
3 month return -36.73
6 month return -27.77
1 year return -40.75
3 year return +493.96
5 year return -70.22
10 year return -

ALIGOS THERAPEUTICS INC Institutional Holdings

Deep Track Capital, LP 7.19

Alyeska Investment Group, L.P. 6.67

Sio Capital Management, LLC 5.44

Woodline Partners LP 4.68

Marshall Wace Asset Management Ltd 4.35

Readystate Asset Management LP 3.29

Vanguard Group Inc 3.24

SummitTX Capital, L.P 2.26

Vanguard Total Stock Mkt Idx Inv 2.06

Renaissance Technologies Corp 1.38

Baker Bros Advisors LP 1.34

Two Sigma Investments LLC 1.31

Hillhouse Capital Advisors, Ltd. 1.23

Verition Fund Managegment, LLC 1.15

LPL Financial Corp 1.07

Citadel Advisors Llc 0.84

Geode Capital Management, LLC 0.77

Vanguard Institutional Extnd Mkt Idx Tr 0.76

Jane Street Group LLC 0.39

Fidelity Extended Market Index 0.37

UBS Group AG 0.26

Quest Partners LLC 0.22

BlackRock Inc 0.21

Fidelity Total Market Index 0.12

Blackrock Extended Mkt Fund CF 0.10

Fidelity Series Total Market Index 0.10

Spartan Extended Market Index Pool F 0.10

Extended Equity Market Fund K 0.09

NT Ext Equity Mkt Idx Fd - L 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.08

NT Ext Equity Mkt Idx Fd - NL 0.07

Vanguard Balanced Index Inv 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

Spartan Total Market Index Pool G 0.05

DFA US Small Cap I 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.03

Fidelity Nasdaq Composite Index 0.03

Avantis US Small Cap Equity ETF 0.02

Dimensional US Core Equity 1 ETF 0.02

ALIGOS THERAPEUTICS INC Market Status

Strong Buy: 2

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

ALIGOS THERAPEUTICS INC Fundamentals

Market Cap 42.14 M

PB Ratio 0.8482

PE Ratio 0.0

Enterprise Value -27.18 M

Total Assets 88.53 M

Volume 58234

ALIGOS THERAPEUTICS INC Company Financials

Annual Revenue FY23:15529000 15.5M, FY22:13907000 13.9M, FY21:4359000 4.4M, FY20:-10548000 -10.5M, FY19:0 0.0M

Annual Profit FY23:12460000 12.5M, FY22:13907000 13.9M, FY21:4359000 4.4M, FY20:-10548000 -10.5M, FY19:null 0.0M

Annual Net worth FY23:-87679000 -87.7M, FY22:-96046000 -96.0M, FY21:-128332000 -128.3M, FY20:-108543000 -108.5M, FY19:-52264000 -52.3M

Quarterly Revenue Q3/2025:741000 0.7M, Q2/2025:965000 1.0M, Q1/2025:311000 0.3M, Q3/2024:1269000 1.3M, Q2/2024:1061000 1.1M

Quarterly Profit Q3/2025:741000 0.7M, Q2/2025:706000 0.7M, Q1/2025:311000 0.3M, Q3/2024:1269000 1.3M, Q2/2024:451000 0.5M

Quarterly Net worth Q3/2025:-31537000 -31.5M, Q2/2025:-15863000 -15.9M, Q1/2025:43088000 43.1M, Q3/2024:-19259000 -19.3M, Q2/2024:5061000 5.1M

About ALIGOS THERAPEUTICS INC & investment objective

Company Information Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 82

Industry Biotechnology

CEO Dr. Lawrence M. Blatt MBA, Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ALIGOS THERAPEUTICS INC FAQs

What is the share price of ALIGOS THERAPEUTICS INC today?

The current share price of ALIGOS THERAPEUTICS INC is $6.81.

Can I buy ALIGOS THERAPEUTICS INC shares in India?

Yes, Indian investors can buy ALIGOS THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy ALIGOS THERAPEUTICS INC shares in India?

You can easily invest in ALIGOS THERAPEUTICS INC shares from India by:

Can I buy fractional shares of ALIGOS THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ALIGOS THERAPEUTICS INC?

ALIGOS THERAPEUTICS INC has a market cap of $42.14 M.

In which sector does ALIGOS THERAPEUTICS INC belong?

ALIGOS THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in ALIGOS THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of ALIGOS THERAPEUTICS INC?

The PE ratio of ALIGOS THERAPEUTICS INC is N/A and the PB ratio is 0.85.